Cereno's PAH drug achieves primary goal in mid-stage trial

Cereno Scientific recently reported success in a Phase 2a trial of its HDAC inhibitor, CS1, for treating pulmonary arterial hypertension (PAH). This positive result led to a near 20% surge in the company’s Swedish-listed stock, {$CRNO.B}, on Monday. CEO Sten Sörensen announced that CS1 met the primary endpoint, demonstrating "good" safety and tolerability, and showed a "positive impact after 12 weeks on clinical parameters significant to both patients and regulatory authorities."

Cereno plans to collaborate with regulatory bodies to advance to a pivotal trial stage. In the Phase 2a study, notable improvements were observed: nine out of 21 patients (43%) had a better REVEAL risk score, and 15 out of 21 patients (71%) either improved or maintained a stable risk score. The REVEAL score is crucial as it predicts survival rates in PAH patients.

Further indicators such as mean pulmonary arterial pressure and functional class, also showed encouraging results. Fourteen out of 21 patients (67%) experienced a sustained reduction in pulmonary arterial pressure. In terms of functional class improvement, seven out of 21 patients (33%) showed progress while 18 out of 21 (86%) had either an improved or stable functional class.

Cereno also revealed findings from a subgroup analysis where 25% of patients had a "remarkable response" to CS1, showing significant reductions in pulmonary vascular resistance.

Additionally, Cereno has entered into a partnership with medical technology firm Fluidda. This collaboration aims to leverage Fluidda's imaging technology to assess structural and functional changes in the lungs and blood vessels, facilitating a detailed examination of CS1's effectiveness. “This collaboration will allow Cereno to use Fluidda’s cutting-edge technology to visualize CS1’s ability for long-term reverse remodeling in PAH patients,” stated Sörensen.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!